`RESEARCH
`
`
`
`APPLICATION NUMBER:
`201281Orig1s000
`
`ENVIRONMENTAL ASSESSMENT
`
`
`
`
`
`
`
`
`
`
`
`
`138
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Section 1.14.1.1 in the labeling section of the electronic submission indicates that
`
`
`
`
`
`
`
`
`
`
`
`
`
`there are both draft carton and container labels in the submission. However, only
`
`
`
`
`
`
`
`
`
`
`
`container (bottle) labels were provided. The firm should explain this discrepancy
`
`
`
`
`
`
`
`and provide the carton labels, if appropriate.
`
`
`
`
`
`
`
`Comments to be Communicated to the Applicant
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Section 1.14.1.1 in the labeling section of the electronic submission indicates that
`
`
`
`
`
`
`
`
`
`
`
`
`
`there are both draft carton and container labels in the submission. However, only
`
`
`
`
`
`
`
`
`
`
`
`container ( bottle) labels were provided. You should explain this discrepancy and
`
`
`
`
`
`
`provide the carton labels, if appropriate.
`
`Since the product needs to be protected from high humidity, your immediate
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`container labels should contain a brief statement about the need to keep the
`
`
`
`
`
`
`
`desiccant packet in the bottle after opening.
`'
`
`
`
`
`Structure Product Labeling (SPL)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Structure Product Labeling, at the end of the package insert will be reviewed at a
`
`
`later date.
`
`
`
`
`ENVIRONMENTAL ASSESSMENT
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`The firm requests a Categorical Exclusion (waiver) from the preparation of an
`
`
`
`
`
`
`
`
`Environmental Assessment under 21CFR§25.31(a) and (b), since the estimated
`
`
`
`
`
`
`
`
`
`
`
`
`
`concentration of linagliptin at the point of entry into the aquatic environment will
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`be below 1 part per billion. The claim for a Categorical Exclusion for metformin
`
`
`
`
`
`
`
`
`
`
`
`HCl is based on 21CFR§25.31(a) because they claim approval would not
`
`
`
`
`
`
`
`
`
`
`
`
`
`increase the use of this previously approved drug since it is expected that those
`
`
`
`
`
`
`
`
`
`
`
`patients switching to linagliptin/metformin HCl tablets will no longer use other
`
`
`
`
`
`
`previously approve products containing metformin HCI.
`
`
`
`
`
`Evaluation:
`
`
`
`
`
`
`
`
`
`The request for the waiver is acceptable
`
`
`
`Reference ID: 2961261
`
`
`
`
`
`Reference ID: 3083109
`Reference ID: 3083109
`
`